Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Banyu Warned about Payment to Doctors Attending Januvia Seminars
October 4, 2010
- Canagliflozin Significantly Reduces HbA1c, Weight in PIIb
October 4, 2010
- Takeda Launches Dexilant in Canada
October 4, 2010
- EMA Recommends Suspension, US FDA Restricts Access to Avandia
October 4, 2010
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Emerging Countries Drive Global Drug Industry: Ms Chui of IMS
September 27, 2010
- Abstract of PII for CBP501 Presented at IMIG2010: CanBas
September 27, 2010
- Prof. Morishita Calls For Creation of Environment Friendly to Bioventures
September 27, 2010
- 30% Market Share for Generics Unlikely to Be Achieved: Mr Mitsuhara
September 27, 2010
- Rozerem Ranked No. 1 in Both HP, GP Markets: RepTrack Survey
September 27, 2010
- Korosho Confirms “Principle of Nondiscrimination”for Generics Applied by Indian Firms
September 27, 2010
- Ritsuo Hosokawa Appointed New Health Minister
September 27, 2010
- Taiyo, Kyowa Should Be More Severely Punished: Nichibyokyo
September 27, 2010
- Bendamustine Launched in Singapore: SymBio, Eisai
September 27, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…